主 办:北 京 中 医 药 大 学
ISSN 1006-2157 CN 11-3574/R

JOURNAL OF BEIJIGN UNIVERSITY OF TRADITIONAL CHINE ›› 2017, Vol. 40 ›› Issue (10): 856-863.doi: 10.3969/j.issn.1006-2157.2017.10.012

Previous Articles     Next Articles

Effects of Cigu Xiaozhi Wan on NF-κB mediated nonalcoholic fatty liver apoptosis*

MA Yanhua1, YANG Shaojun2#, BAI Zhouxia3, XU Sanpeng1   

  1. 1 Gansu University of Traditional Chinese Medicine, Gansu 730000, China;
    2 Beihai traditional Chinese Medicine Hospital of Guangxi, Guangxi 536000, China;
    3 Department of Clinical Laboratory, Affiliated Hospital of Gansu University of Traditional Chinese Medicine, Gansu 730020, China
  • Received:2017-04-20 Online:2017-10-10 Published:2017-10-10
  • Supported by:
    Regional Science Project of National Science Foundation of China(No.81460710)

Abstract: Objective To study the effects of Cigu Xiaozhi Wan (Sagittaria Lipid-reducing Pill, CGXZW) on the expression of nuclear factor-κ gene binding(NF-κB), B-cell lymphana-2(Bcl-2) and Bcl-2 associated X protein(Bax) in rats with nonalcoholic fatty liver disease (NAFLD) and explore the therapeutic mechanism of toxin-removing phlegm-resolving method. Methods SPF grade male Wistar rats (n=60) were randomly divided into six groups: normal control group, model group, low-dose, mid-dose and high-dose CGXZW groups, and pioglitazone hydrochloride group (n=10 in each group). All rats were fed with high-fat diet to establish NAFLD model except those in the normal control group. After 6 weeks of intervention, all the experimental animals were sacrificed. Liver and serum sample were taken. Serum samples were drawn to test liver function and blood lipid by automatic biochemical analyzer. The liver histopathological changes were observed under microscope with HE staining.The ultrastructure of liver cells was observed by using transmission electron microscope. The expression of NF-κB, Bcl-2 and Bax in rats of all groups was detected by using Western blot. Results Compared with the normal group, the serum levels of alanine aminotransferase(ALT), aspartate transaminase(AST), triglyceride(TG), total cholesterol(TC) and low density lipoprotein-cholesterol(LDL-C) were significantly increased (P<0.01) in the model group; liver tissue of NAFLD rats showed moderate to severe steatosis and hepatocytes apoptosis. The expression of NF-κB and Bax in liver tissue of rats were increased significantly (P<0.01), while the expression of Bcl-2 and Bcl-2/Bax ratio were significantly reduced (P<0.01) in the model group. Compared with the model group, the serum levels of ALT, AST, TG, TC and LDL-C were decreased significantly in all-dose CGXZW groups (P<0.01); the expression of NF-κB and Bax were significantly reduced (P<0.01) whereas the expression of Bcl-2 and the ratio of Bcl-2/Bax was increased (P<0.05). CGXZW high-dose group was superior to pioglitazone hydrochloride group in terms of down-regulation of NF-κB and up-regulation the expression of Bcl-2 (P<0.01) whereas pioglitazone hydrochloride group was better than all CGXZW groups in down-regulating the expression of Bax and up-regulating the ratio of Bcl-2/Bax (P<0.01). Conclusion Sagittaria Lipid-reducing Pill can significantly improve liver function and reduce blood lipid level in NAFLD rats, upregulate the expression of Bcl-2, decrease the expression of NF-κB and Bax, and inhibit liver cell apoptosis. It could be used in the prevention and treatment of NAFLD.

Key words: Sagittaria lipid-reducing Pill, nonalcoholic fatty liver disease, apoptosis, NF-κB, Bcl-2, Bax, rats

CLC Number: 

  • R285.5